The cardinal question for a person developing seizures is 'What is the likelihood that they will go away?' 'Prognosis' refers to the possible outcomes of a disease and the frequency at which they can be expected to occur. Prognostic factors may include demographic features, disease-specific indicators (e.g. seizure frequency, aetiology of epilepsy) or comorbidity. Such factors do not necessarily cause the outcome, but they are associated strongly with the outcome measured. They are distinct from risk factors-which are associated with the initial development of the disorder.
RECURRENCE OF SEIZURES AFTER A FIRST SEIZURE
The overall risk of recurrence after the first seizure is an important aspect of prognosis. It should be borne in mind that factors affecting recurrence will not necessarily be the same as those leading to chronic epilepsy.
The rate of recurrence
Estimates vary for the risk of recurrence after a single seizure-from 27% to 81% [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The different results may be explained by methodological variations between studies 13, 17 . The earlier after the initial seizure that patients are enrolled into a study, the higher the reported rates of recurrence. Late enrolment, studies in which there is delay between first seizure and assessment, or retrospective design biases studies towards lower recurrence rates 2, 3, 5, 8, 16, 18, 19 , because most recurrences occur within the first few weeks 13 and the risk of seizure recurrence falls with time 9, 12, 17, 20 .
As many as one-third of patients do not present until they had had more than two seizures 21 and so would be excluded from some studies of seizure recurrence 5, 15 . Patients with generalized tonic-clonic seizures are likely to present earlier than those who have partial seizures, which may also bias studies.
Another important consideration is the frame of the study and selection bias. Studies based in EEG, neurology or paediatric clinics are not based on the same population as community-based ones-clinic-based groups have more severe seizure disorders 4, 6, 10, 12, 22 .
Retrospective data will inevitably give a bias towards more severe cases with recurrence. Two retrospective studies of recurrence after first seizure report very different rates: Annegers et al. 11 reported rates of 36% by 1 year and 56% by 5 years, compared with 81% overall by Goodridge and Shorvon 7, 23 .
The only prospectively designed, community-based study of seizure recurrence is the NGPSE, which gave an overall rate of seizure recurrence of 67% by 1 year and 78% by 3 years 13 .
Single seizures have a lower incidence rate than epilepsy, implying that most patients will have two or more seizures. The alternative explanation-that single seizures are a more infrequent and different entity from epilepsy-does not seem biologically plausible.
Seizure recurrence after diagnosis of epilepsy
One study of seizure recurrence has looked at recurrence after two unprovoked seizures 24 . It attempted to avoid some of the above-mentioned biases by only recruiting patients within 24 hours of a first seizure, but excluded patients who at first presentation could be said to have seizures once a medical history was taken. They report the recurrence rate after first seizure as 33% (CL = 26, 40); among those who had a second seizure there was a 57% (CL = 45, 70) chance of having a third at 1 year and 73% (CL = 59, 87) at 4 years. Although it is stated that no patients who had a second seizure were lost to follow-up, no figure is given for loss to follow-up between first and second seizure, which makes interpretation difficult. In addition, its population is drawn from neurology patients and EEG referrals. There is an excess of male subjects who account for 70% of the group.
Factors affecting rate of recurrence
Several prognostic factors for recurrence have been identified, but they are not without controversy. Age of onset below 10 years 22 or 16 years 3, 4, 13, 25 , or over 65 years 12, 13, 26, 27 has been correlated with recurrence. This has not been replicated in other similar studies 6, 11, 14 . Sex does not correlate with prognosis for early recurrence 6, 11 .
Partial seizures are associated with poorer outcome for recurrence 4, 7, 9, 11, 13, 14, 25 , although not all studies examining seizure type have found this correlation 6 . Nocturnal seizures 12 and mixed seizure types 22 have also shown higher recurrence rates.
Aetiology also shows a correlation with prognosis; congenital neurological deficits predict higher rates of recurrence 11, 13 . Seizures after stroke seem relatively benign; they are common, affecting 11.5% by 5 years, but half of these are single seizures from first cerebrovascular episode in a prospective communitybased study 28 . Head injury may be associated with a higher rate of recurrence, but was reported in a study that had a low rate of recurrence overall and it, together with other studies, fall within the range of expected seizure recurrence 29, 30 . Remote causes of epilepsy, which included conditions such as stroke or tumour, increased the rate of recurrence-in the Rochester study from 45% in idiopathic seizures to 77% 4, 6, 11, 14, 16, 27, 31 -although other studies, which examined remote causes, either found that only tumours increased the recurrence rate 12 or did not find an effect 13 . Abnormal neurological examination has been correlated to recurrence 8, 11 .
Some underlying genetic syndromes entail a lifelong tendency to seizures, which may either respond to medication-as in juvenile myoclonic epilepsy 32 and autosomal dominant temporal lobe epilepsy 33 -or not respond-as in nocturnal temporal lobe epilepsy 34 ; others have a very benign prognosis. Less specifically, a family history of seizure disorders increases the risk of recurrence 6 .
The presence of an EEG abnormality is more controversial, but some studies have identified this as a risk factor for recurrence 5, 6, 8, 11, 14, 16, 26, 31, 35, 36 .
These factors reflect the heterogeneity underlying the diagnosis of 'epilepsy' and imply that a differing case mix will influence reported recurrence rates.
Effect of medication on recurrence after a first seizure
In most epidemiological studies of epilepsy, the descriptive design does not influence the prescription of antiepileptic medication. This means that patients whose seizures are deemed to be more severe-in either seizure type or underlying aetiology-are more likely to be treated. This biases the results. Descriptive studies have found that the risk of seizure recurrence is not altered by medication 6, 11, 14, 25 , but studies have reported a reduced chance of recurrence 9, 12 .
The only study that examines this appropriately, in the context of a placebo-controlled trial of antiepileptic drugs after a first seizure, found a threefold increased risk of seizure recurrence in the untreated group by 2 years 26, 27 . There are some reservations about this study's design-it excluded patients with previous seizures and examined only generalized seizures.
THE REMISSION OF EPILEPSY
Remission of epilepsy is the seizure-free period experienced by a patient who has had one or more seizures. It is usually defined as being of 1-5 years' duration. Terminal remission is when the remission continues to the end of follow-up. There are various factors that influence the likelihood of achieving and maintaining remission.
Methodological considerations
The interpretation of epidemiological studies requires an appreciation of potential pitfalls in study design.
Definition and classification of epilepsy
By convention, the diagnosis of epilepsy is made only after a second unprovoked seizure. Seizures can be the symptomatic expression of a wide range of conditions and, for this reason, the use of the term 'the epilepsies' is more appropriate than 'epilepsy' 37 . Single, acute, symptomatic seizures and febrile convulsions are not considered to be epilepsy.
The study of the prognosis of epilepsy is confounded by the diversity of underlying diagnoses; it is in fact the prognosis of a diverse group of conditions of known aetiologies or cryptogenic origin. In addition to the differing risks for the underlying conditions, there are the risks of the seizures themselves.
The difficulty of diagnosis
The case definition of epilepsy is deceptively clearcut: 'two or more unprovoked epileptic seizures'. A key difficulty is diagnosing the seizure. Seizures are brief, pleomorphic-albeit often stereotypical in an individual-and unpredictable. The diagnosis is based on the history of the episodes, with some support from investigations. The witnessed account, even when it is available, may be difficult to interpret for many reasons, among which poor observation or capacity to describe the seizure and inaccuracy of second-hand accounts are common sources of error. In addition, there is variability in how clinicians interpret the information. This leads to diagnostic variation; for example, in some reports 20% of patients referred to specialist epilepsy clinics are diagnosed as not having epilepsy 38, 39 . Interobserver reliability has been found to be as low as a kappa value of 0.58 in one study 15 . In the Rochester study, time from first seizure to diagnosis took over 6 months in 50% of patients and over 2 years in 30% 40 . This lag time means that, when studies exclude patients without a definite diagnosis, considerable bias occurs; certain groups will be excluded more than others-elderly people, those with learning difficulties, those with infrequent or nocturnal seizures-as all these patients are less likely to be able to provide a clear account of the seizure. Most studies, except the NGPSE, do not address this important clinical issue 4, 5, 7, 11 .
Adding to the difficulty of diagnosis are other paroxysmal conditions, the presentation of which may be confounded with epileptic seizures, such as syncope, vertigo, panic disorders, hyperventilation syndrome 41 . No investigation is definitive or highly reliable in the diagnosis of seizure disorders.
Seizures that occur during a metabolic disturbance or an acute illness are not considered as epilepsy because they are deemed to be caused by a pathological process, which, because of its transient nature, cannot be assumed to provoke further seizures; as a result, a continuing tendency to seizure activity will not occur. The distinction is, however, conventional and not the result of a clear-cut physiological demarcation.
The difficulty in diagnosis remains throughout the course of epilepsy; thus, non-epileptic seizures will inflate the figures for chronic epilepsy although it can be difficult to estimate how much they contribute to the 20-30% of patients who will suffer chronically 42 .
Clearly, it is important that studies take the issue of diagnosis seriously, so that comparison of results may be made.
Difficulty in classification of epilepsy
A comprehensive syndromic classification was commissioned by the ILAE 41 . It was drawn up with the intention of having a reliable clinical tool for the classification of epilepsy and to allow comparison between studies. However, it may be difficult to apply; one study that assessed its reliability found that this was only 50%.
In attempting to classify epilepsy, some syndromes are clear-cut, e.g. juvenile myoclonic epilepsy; however, despite extensive investigation and prolonged follow-up, many patients remain difficult to classify and, in addition, several aetiologies may underlie what is the 'same' epileptic syndrome.
Moreover, the early remission of most epilepsies allows little time for observation and investigation of the active disorder. In most reliable studies, only half of the cases are classified. In children, this poses greater problems and one way of handling data is to group 'disputable events' separately-when using such a demarcation it was found that these children had a 10% chance of seizure recurrence versus 54% overall 16 .
Population characteristics
Only community-based studies provide the full breadth of the epilepsies because some patients may never be referred for specialist opinion and the choice of specialist is wide 43, 44 . Clinic-based studies are influenced by referral patterns, patient characteristics and seizure severity; however, many studies are clinic based 9, 22, [45] [46] [47] [48] [49] [50] [51] [52] [53] .
The community studied will also influence findings. In Rochester, USA the population is homogeneous, white, relatively affluent and of northern European descent 40, 54, 55 .
Criteria for inclusion and exclusion
The criteria for inclusion and exclusion will affect outcome measures. The exclusion of patients who experience early recurrence seems likely to improve the overall prognosis. When single seizures are excluded, those patients with a lower tendency to recur are left out and remission rates are likely to be lower 21, 40, 55, 56 . Similarly, an atypical population with more severe seizures is selected if only patients taking AEDs are included 50 . Another bias that is difficult to interpret is added if only patients who have had an EEG are included 57 . In one study, FCs were not excluded but lumped together with other seizure types 58 .
Some studies exclude patients with abnormal neurology before the seizure 47 .
Temporal aspects
A turning point in the understanding of the natural history of seizure disorders came with the appreciation that patients should be followed from the same point in their illness-whether this is a first or second seizure, or first presentation. If this is not done, there is a tendency to find poor outcome because of the inclusion in the cohort of those with ongoing seizures and more severe epilepsy 37, 59, 60 . This underlies the poor prognosis of epilepsy reported in older studies 61, 62 .
Most patients, if they are going to remit, go into remission early in the course of their illness. For example, in the Rochester study the net probability of entering remission was 65% over 10 years but, if remission had not been achieved by 5 years, the chance of subsequent remission was only 35% 55 .
Definition of remission
Different definitions of remission lead to difficulty comparing studies. The time in remission varies from 1 to 5 years 16, 40, 49, 63 . Whether any seizure-free period is included as remission or only counted if it is terminal remission 7, 23 , and whether AED status is considered, are other sources of variability 40, 55 .
Generally, AED status is not considered as part of the definition of remission, and many studies report both terminal and non-terminal remission rates.
Prospective design
Prospective studies yield better data because they can avoid bias by careful study design; information is available that may not have been recorded meticulously in normal clinical practice. This needs greater resources.
Length of follow-up is central to the prognosis of a chronic relapsing and remitting condition, and the further back a retrospective study delves the more bias must enter the study. Some of the Rochester data go back to 1935 55 ; this is the same year that Faxén wrote a critique of the definition of epilepsy, which seems so far removed from current concepts of seizure disorders 59 .
Length of follow-up
In a chronic disorder, the length of follow-up influences the remission rate. Studies of newly diagnosed patients followed for 1 or 2 years give high remission rates-of the order of 80% 16, 22, 64 . However, remission is only meaningful if the remission is lengthy and hence the follow-up must be prolonged. Prospectively designed studies are now reporting decades of followup data 55, 65, 66 .
Loss to follow-up
Loss to follow-up can damage the validity of a study because it cannot be assumed that those lost are identical or even similar to the rest of the group. Despite the statistical tenet that the non-responders do not resemble the responders, many groups have just ignored this problem 63 .
An alternative way of handling those lost to followup in actuarial analysis is to assume that they have not remitted, which will decrease remission rates and give a pessimistic view of outcome.
Statistical analysis
Early in the course of their epilepsy, most patients will remit; fewer remit with the passage of time. For this reason, it is inappropriate to give the proportion of patients going into remission if the cohort is not being followed from the same point in the illness.
Life-table analysis can handle only a single endpoint but, in epilepsy, patients may go in and out of remission and may therefore need more sophisticated statistical analysis. If both cumulative and terminal remission are calculated, this can, to some extent, be accounted for. As only 12% of patients have this intermittent pattern, the bias may not be excessive 7 .
In the statistical analysis of prognostic factors, the use of univariate analysis has confounded many studies. Unifactorial models are not appropriate for multifactorial disease. Coupled with the cut-off for statistical analysis of P < 0.05, which means that 1 in 20 factors is found to be significant by chance alone, inevitably studies will not always agree.
The effect of treatment on remission
The effect of treatment on epilepsy has been a confounder in many studies of the condition. When studying a condition, ideally one would want an unbiased set of factors acting on the whole cohort. If treatment is being used, as indeed it is in every modern descriptive study, this should be in a randomized fashion.
Interventional studies have demonstrated that most patients presenting with epilepsy entered long-term remission when treated 10, 22, 50, [67] [68] [69] [70] [71] . The studies that found a good prognosis for patients presenting with seizures were interpreted as causal-good prognosis was seen as a product of appropriate early intervention. Although it was argued by most authors at that time that treatment improved prognosis there is little evidence to uphold this view, and gathering evidence from interventional and epidemiological studies to refute it.
A recent study examining the effect of treating patients after their first or subsequent generalized tonic-clonic seizures has shown no difference in longterm (1 or 2 year) remission rates 27 .
Drug withdrawal is an important cause of seizure relapse 72 .
Natural history
To study remission it is important to consider the natural history of the untreated condition. Epilepsy has had effective treatments since bromide salts were used in the 1850s, and so it has been difficult to study drugnaïve patients. The untreated patients in cohorts are unlikely to be similar to the treated patients and often have milder seizures 73 .
Studies in developing countries
In conditions showing no remission and long survival, lifetime prevalence rates will approach prevalence rates, the difference being attributable to differential deaths caused by the condition or its complications. In the developed countries, the difference between these rates has been attributed to drug-induced remission. There is evidence that the incidence rates of epilepsy in the developing world are higher mainly as the result of acute bacterial infection, chronic viral and parasitic infection, poor neonatal outcome and accidents 37, 74 . Prevalence rates should be higher in developing countries (allowing for related mortality) if the notion that failure to provide early treatment for epilepsy promoted chronicity and intractability was true. However, large studies of the epidemiology of epilepsy in these countries have reported rates that are very similar to those in the developed world 75, 76 . There are exceptions to this, but these studies are in groups that have high rates of inherited neurodegenerative disorders, such as the Wapogoro of Tanzania and residents of Gran Bassau county, Liberia [77] [78] [79] [80] [81] .
In Ecuador, a population-based study found a cumulative incidence rate of 1.9% among a population of 75 000, the prevalence rate of active epilepsy being 0.7%, which implies a remission rate of at least 50% 82 . Similar observations were made in a smaller study from Malawi 83 . This supports the idea that spontaneous remission may occur 37 .
An additional argument against the development of intractability is that studies have shown good response rates for treatment initiated in unselected drug-naïve patients after many years of active epilepsy 51, 77, 78, 84, 85 .
Overall remission rates from hospital-based studies

Retrospective studies
Despite the biases discussed above, there have been a large number of studies in recent decades that are clinic based and retrospective. The Japanese group have examined the outcome of seizures among 1868 patients seen in 20 clinics. Follow-up was problematic because these patients constituted only 42% of those who had attended these clinics during the frame of the study. The remission rates for 3, 5 and 10 years were around 58% 86 . In Aarhus, Denmark, a study of remission in 1505 patients registered at diagnosis found that 47% of patients with primary generalized epilepsy were in remission compared with 28% of those with complex partial seizures; these were crude percentages without a long follow-up 87 .
Studies of newly diagnosed patients
Studies in clinic-based populations have reported the effect of treatment among newly diagnosed patients 50, 64, 67, 69, 71, [88] [89] [90] [91] . Despite some differences in their case ascertainment, they discuss the outcome in terms of remission of seizures of 1, 2 or 5 years. The reported 1-year remission rates vary between 58% and 95%, most falling between 65% and 80% 16 . There is less unanimity over what features predict poorer outcomes. Partial seizures are thought to have a worse prognosis for seizure control than generalized seizures (whether from generalized epilepsy or in patients with secondarily generalized seizures only) 71 . Multiple seizure types have also been linked with worse prognosis, as have associated neurological deficits and behavioural or psychiatric disturbance 22, 50 . A poorer outcome has been reported in those who had experienced a high-frequency tonicclonic seizure before receiving any treatment 10, 50 . In one study, there was a worse prognosis if there was a family history of epilepsy 10 .
There are only clinic-based studies for prognosis of specific epilepsy syndromes. Benign partial epilepsy with centrotemporal spikes has a very good prognosis and practically all patients remit by puberty 92, 93 . In contrast, typical absence epilepsy has a worse prognosis than was previously believed and two-thirds of patients remit 16, 94, 95 .
Population-based studies of remission
Retrospective studies have also described the remission of seizures in patients diagnosed with epilepsy and started on antiepileptic medication at some point in the past.
In the UK, patients with chronic grand mal epilepsy were surveyed and 42% had no seizures during that year 43 .
In the Rochester study, remission was defined as 5 years without seizures; at a year after diagnosis, 42% had entered into a period of remission and at 10 years 65% were in remission; at 15 years 76% were in a 5-year remission 40, 55 .
The Tonbridge general practice study, in which remission was defined as a 2-year period without seizures, showed similarly that 73% of patients overall were in remission 7, 23 .
In both Rochester and Tonbridge, most of the patients who entered into remission had done so by the end of the first 2 years. Thus, as time passed from diagnosis, the chance of treated active epilepsy remitting diminished.
Drug-withdrawal studies
As 70-80% of patients on AEDs become seizure free, it is common clinical practice to consider withdrawal once a patient has been in remission for a 'reasonable' length of time. A number of studies address this issue 58, 87, 91, [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] . The range of probability of relapse has varied from 11% to 41%. Studies of childhood epilepsies fall into the bottom end of this range and adult studies towards the upper end of the range. The rate of relapse is highest in the early months after withdrawal 97, 102, 103 .
There is considerable variation in methodology. Older studies considered a reasonable seizure-free period or minimum treatment time to be up to 5 years 100 . More recent studies tend to consider shorter periods 104, 105 . A prospective comparison of prognosis in children undergoing AED withdrawal after 6 or 12 months of seizure freedom found no difference in outcome 98, 100, 105 . Exclusion criteria have varied; some investigators considered it unreasonable to withdraw medication if either the EEG had not returned to normal 102 or the patient had a neurological deficit 103 . Patients whose seizures relapsed during the withdrawal period, rather than after complete withdrawal, were excluded from analysis in one study 103 .
The study that is not only the largest but also the best designed 72, 104 found a risk of relapse of 41% within 2 years of drug withdrawal, compared with a rate of 22% among the group randomized to continuing with medication. This divergence between relapse rates was maximal between 1 and 2 years, after this, the risk of relapse was higher in those 'remaining on treatment'. This counterintuitive finding is most probably the result of the decision of patients, with or without medical supervision, to stop their medication, but because this is an assumption it needs to be treated circumspectly. It would appear, however, that a substantial number of patients are in remission and will remain so without AEDs, whereas another group depend on their medication for seizure control.
It may be useful to examine not only the course of the drug withdrawal in such patients, but also how this relates to initial seizures and response to AEDs 106 .
Drug-withdrawal studies have found the following factors related to poor outcome:
• total number of seizures 87, 107 ,
• short seizure-free period 72, 103, 104 ,
• seizures after starting antiepileptic medication 58, 100, 104, 108 ,
• polytherapy 72, 102-104 ,
• duration of treatment 109 ,
• generalized tonic-clonic seizures 72, 100, 104 ,
• myoclonus 72, 104 ,
• partial seizures 58, 72, 105, 109, 110 ,
• multiple seizure types 58, 100 ,
• an abnormal EEG 97, 98, 103-105, 107-109, 111, 112 ,
• symptomatic epilepsy 52, 58, 97, 100, 103, 105, 108 ,
• previous FCs 98 ,
• withdrawal of medication in adolescence 97 ,
• none of these 99 .
Factors affecting prognosis for remission
Age
The effect of age on prognosis appears to follow a Jshaped curve. Most studies have found that early onset has a better prognosis than later-onset epilepsy 40, 55, 57 . However, studies that have included enough children show that prognosis is worse if epilepsy starts in the first year or two of life 17 , reducing the 4-year remission rate from 69% to 47% in one study 107 .
There is an interaction between aetiology and age in young-onset epilepsy-children with spastic quadriparesis accounted for 75% of children whose onset of epilepsy was under 2 years-a lower age of onset than in control epilepsy groups 53 ; similarly infantile spasms start before 1 year and have a particularly poor prognosis (in one study only 16% were alive without sequelae 48 ). On the other hand, some of the benign epilepsies of childhood start later, such as benign partial epilepsy with centrotemporal spikes, where the onset is between 3 years and puberty, or absence epilepsy starting at around age 6-8 years.
Seizure type
It is generally held that seizure type has a strong effect on prognosis; however, a close examination of the literature reveals that studies do not classify seizures in a way that allows easy comparison and, in addition, some findings are contradictory.
Partial seizures are thought to have a worse prognosis for seizure control than generalized seizures (whether from generalized epilepsy or in patients with secondarily generalized seizures only) 4, 66, 71, 75, 98, 110 . The following have also been linked with worse prognosis:
• multiple seizure types 49, 50, 58 ,
• atonic seizures 66 ,
• infantile spasms 17 ,
• generalized tonic-clonic seizures 57 ,
• status epilepticus 4, 113, 114 .
Some studies have not found seizure type to be helpful for prognostication 63, 115 .
Aetiology
Unlike clinic-based or retrospective studies 47, 57, 86, 116, 117 , it has been shown that there is little difference in prognosis between idiopathic epilepsy and symptomatic epilepsies in prospectively designed, community-based studies 7, 23 . For example, in Rochester, USA 74% of patients with idiopathic epilepsy entered 5-year remission, which was not significantly different from the symptomatic group 55 . In this study, however, the subgroup of symptomatic epilepsy who had congenital neurological dysfunction did far worse and only 46% had entered remission at 20 years. The finding that remote symptomatic seizures in young children do worse than idiopathic seizures in children is supported by a number of other studies 17, 49, 66, 113 .
Electroencephalographic findings
The study of the importance of EEG abnormality has been hampered by the clinic-based nature of the investigation, limiting the extrapolation of findings to the community. For example, in the large communitybased cohort from Rochester, where there is ready access to medical investigations, 71% had had an EEG; it is reasonable to believe that those who were not investigated differed from the rest of the group 57 .
The association of different types of abnormalities in specified subgroups has been correlated with poor prognosis for remission, i.e. generalized activity on the EEG in patients with generalized tonic-clonic seizures 57 , abnormal background or paroxysmal activity in complex partial seizures 47 , paroxysmal frontal or anterior temporal regions 86 , among others. However, not all studies show an effect 63, 118 .
Another limiting factor in studies of EEG abnormality and prognosis for remission is that some studies based inclusion criteria on the results of the EEG 46, 57, 75 .
Early seizure pattern and its effect on subsequent remission
The temporal pattern of epilepsy has been neglected. There are only two reported studies 7, 23, 119 . One described the pattern of seizures in 181 patients with chronic epilepsy who attended an epilepsy clinic, and the other of 180 patients identified in the community. These groups were comparable in terms of age and length of history. Three patterns of epilepsy were described: a burst pattern (seizures at outset with early prolonged remission), intermittent (as for burst pattern, although after a remission of at least 2 years there was a relapse) and continuous seizures from outset. The burst pattern accounted for 65% of cases in the community, 25% having continuous epilepsy from the outset, and 12% had remission followed by relapse. This contrasted with those attending the specialist clinic, where only 22% had ever experienced a remission at any stage in their condition 7, 23 . Thus, the statement that epilepsy is a chronic remitting and relapsing condition can be applied only to a minority of patients who have seizures.
A separate issue is whether number or frequency of seizures at the onset of the disorder is predictive of remission. A worse prognosis has been reported in those who experienced high-frequency tonic-clonic seizures before receiving any treatment 10, 22, 50, 120 , or without reference to medication 49, 66, 69, 113, 121 .
Other prognostic factors
A family history of epilepsy has been correlated with a worse prognosis 10, 69 , but this was not found in other studies 63 .
MORTALITY FROM EPILEPSY
There is an increased mortality rate among patients with epilepsy. This has a peak in the first year after diagnosis as a result of those causes of epilepsy that have high case fatality, such as secondary brain tumours, subarachnoid haemorrhage and stroke 122 . However, the mortality rate remains elevated, particularly among young adults with severe active epilepsy. This finding is consistent in many studies. Mortality is particularly high in those with cryptogenic seizures, and idiopathic epilepsy and severe active epilepsy; however, the standardized mortality ratio (SMR) for patients whose seizures are in remission is also high at around 1.8 [123] [124] [125] .
Demographic features are important; men have higher SMRs than women with epilepsy, especially in those aged up to 40 years where death as a result of other causes is infrequent. Among the over-75s, in whom the death rate is high, the added risk of epilepsy is much smaller.
Seizure type is important: absence seizures in isolation display no excess mortality, whereas myoclonic seizures have an SMR of 4.1 124 .
The most common causes of death among those with epilepsy are chest infections, neoplasia, and epilepsy-related deaths and accidents. Bronchopneumonia is the most common cause of increased SMR in this group, with a rate of 1.7-7.9 124, 126, 127 . It has been postulated that this is because of peri-ictal aspiration.
Tumours, with or without the inclusion of brain tumours, are more frequent in patients with epilepsy 123, 124, 127 . However this seems to be caused by cancer diagnosed before the diagnosis of epilepsy 124, 126 .
Epilepsy-related deaths are divided into those caused by status epilepticus, sudden unexpected death (SUDEP) or accidents. It has been postulated that death associated with a seizure is the result of autonomic instability, including apnoea, bradycardia and cardiac arrhythmia, which can be recorded during seizures 128 . The difference between seizure-related death and SUDEP is that, in the former, the seizure is witnessed; in the latter, a patient with epilepsy is found dead and there is no cause found post mortem. The annual incidence of SUDEP in an outpatient cohort of a specialist epilepsy service was 1 in 200 patients with chronic epilepsy 129 .
SMRs for accidents and trauma are raised. Suicide is increased among those with epilepsy, especially if severe, of relatively recent onset and arising in the temporal lobe 126 . The NGPSE cohort has not demonstrated this as a cause of excess mortality, despite the inclusion of people whose epilepsy falls into these categories 122 .
CONCLUSION
There is debate about why some patients achieve remission and others do not. It has been suggested that the failure to control seizures early on in the illness renders the epilepsy more resistant to treatment in the future, perhaps because of secondary structural changes within the brain 61, 69, [130] [131] [132] [133] . However, an equally consistent explanation would be that the epilepsy in any individual patient has an inherent 'treatability', and that severely affected patients will be difficult to control from very early in their condition 37, 73, [134] [135] [136] . The only way of clarifying whether early treatment has an impact on future prognosis is to carry out a randomized trial; it was recently reported that there was no improvement in long-term outcome with treatment after first, compared with later, generalized tonic-clonic seizures 27 .
There remain questions and controversies regarding the prognosis for remission in the epilepsies; and importantly these include the effect of aetiology and syndromic classification on the prognosis of epilepsy (community based to avoid the severity bias of clinicbased studies), and the effect of treatment on prognosis for remission 137 .
